EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study

Jerzy Windyga iD, Shashikant Apte, Melissa Frei-Jones, Teruhisa Fujii, Chuhl Joo Lyu, Laura Villarreal Martinez, Jameela Sathar, Oleksandra Stasyshyn, Huyen Tran, Nadezhda Zozulya, Renée Brown Frandsen, Jesper Skov Neergaard und 2 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14277 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Jerzy Windyga und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Me…. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk (Denmark).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to characterise baseline disease and treatment burden in a large population with haemophilia A/B, both with (HAwI/HBwI) and without (HA/HB) inhibitors.

Methods

The prospective, non‐interventional explorer6 study included patients ≥12 years old with severe HA, severe/moderate HB or HAwI/HBwI of any severity, treated according to local standard of care (excluding previous/current exposure to concizumab or emicizumab). Baseline characteristics and historical clinical data were collected and patient‐reported outcomes, including treatment burden, were assessed.

Results

The explorer6 study enrolled 231 patients with haemophilia (84 HAwI/HBwI) from 33 countries. At baseline, patients with HA/HB treated with prophylaxis had the lowest median annualised bleeding rates (ABRs; 2.0), irrespective of haemophilia type; of these patients, 27.5% (HA) and 31.4% (HB) had target joints. Patients with HAwI/HBwI treated episodically reported the highest treatment burden. Of these patients, 28.5% (HAwI) and 25.1% (HBwI) performed sports activities in the month before screening.

Conclusion

Despite receiving routine clinical care, historical and baseline information from patients enrolled in explorer6 showed that patients with HA/HB treated episodically and patients with HAwI/HBwI had higher ABRs, higher treatment burden and participated in sports less than those with HA/HB treated with prophylaxis. Emerging treatments could be beneficial in addressing these unmet medical needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AAdolescentAdultChildFemaleHumansMaleMiddle AgedYoung AdultCost of IllnessDisease ManagementFactor VIIIHemophilia BHemorrhageProspective StudiesSeverity of Illness Index

Stichwörter der Autor:innen

haemophilia Ahaemophilia Bhealth‐related quality of lifephysical activitysymptom burden

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Sahyadri Speciality Hospital, Pune, India.
  • Pediatric Hematology-Oncology, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
  • Hiroshima University Hospital, Hiroshima, Japan.
  • Yonsei University Severance Hospital, Seoul, Korea.
  • Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico.

ORCID-Profile: Jerzy Windyga, Johnny Mahlangu

Förderung

  • Novo Nordisk (Denmark)

Zitieren

APA

Windyga, J., Apte, S., Frei-Jones, M., Fujii, T., Lyu, C. J., Villarreal Martinez, L., Sathar, J., Stasyshyn, O., Tran, H., Zozulya, N., Brown Frandsen, R., Neergaard, J. S., Thaung Zaw, J. J., & Mahlangu, J. (2024). Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study. European Journal of Haematology. https://doi.org/10.1111/ejh.14277

Vancouver

Windyga J, Apte S, Frei-Jones M, Fujii T, Lyu CJ, Villarreal Martinez L, et al. Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study. European Journal of Haematology. 2024. doi:10.1111/ejh.14277

BibTeX
@article{Windyga2024,
  author = {Windyga, Jerzy and Apte, Shashikant and Frei-Jones, Melissa and Fujii, Teruhisa and Lyu, Chuhl Joo and Villarreal Martinez, Laura and Sathar, Jameela and Stasyshyn, Oleksandra and Tran, Huyen and Zozulya, Nadezhda and Brown Frandsen, Renée and Neergaard, Jesper Skov and Thaung Zaw, Jay Jay and Mahlangu, Johnny},
  title = {Disease and treatment burden of patients with haemophilia entering the explorer6 non‐interventional study},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14277}
}
Kostenlos starten →